Oncocyte will receive upfront cash payments after transferring and installing DetermaRx, in addition to certain tests after it achieves inclusion in the US Comprehensive Cancer Network.
The collaboration, through which Hummingbird will have access to Tempus' TIME Trial Network, is focused on advancing the HER3-targeted agent, HMBD-001.
CHMP issued a positive recommendation for Daiichi Sankyo/AstraZeneca's antibody-drug conjugate following positive results from the DESTINY-Breast01 trial.
Through this partnership, the companies hope to help oncologists make better testing and treatment decisions, as well as improve clinical trial matching.
The European Commission will review CHMP's opinion based on the Keynote-177 data and is expected to issue a final decision in the first quarter of 2021.
The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.
The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.
The agency recommended the drug based on the results from the Phase III ALTA-1L trial, and after Takeda agreed to offer the drug to NHS England at a discount.
The test, called Immunoscore, is designed to predict the risk of relapse in early-stage colon cancer by measuring host immune responses at tumor sites.
With clinical sequencing data for almost 400 appendiceal cancer cases, researchers identified somatic differences in individuals diagnosed with the disease before the age of 50.
The FDA has issued a clinical hold on the company's Phase I/II clinical trial of BPX-601 in patients with advanced pancreatic, gastric, and prostate cancer.
The study, slated to begin in the first half of 2021, follows recent discussion with the FDA and promising Phase II data presented at the ASH annual meeting.
Researchers uncovered genetic loci that may influence why childhood cancer survivors of African ancestry are more likely to develop therapy-linked cardiomyopathy.
As part of the deal, Atara will receive $60 million upfront and be eligible for up to $610 million in milestone payments, as well as tiered royalties based on net sales.
